- Home
- BTG vs MRUS Comparison
BTG vs MRUS Comparison
Compare BTG & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTG
- MRUS
- Stock Information
- Founded
- BTG 2006
- MRUS 2003
- Country
- BTG Canada
- MRUS Netherlands
- Employees
- BTG N/A
- MRUS N/A
- Industry
- BTG Precious Metals
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- BTG Basic Materials
- MRUS Health Care
- Exchange
- BTG Nasdaq
- MRUS Nasdaq
- Market Cap
- BTG 4.9B
- MRUS 4.1B
- IPO Year
- BTG N/A
- MRUS 2016
- Fundamental
- Price
- BTG $3.32
- MRUS $66.16
- Analyst Decision
- BTG Buy
- MRUS Strong Buy
- Analyst Count
- BTG 3
- MRUS 13
- Target Price
- BTG $4.25
- MRUS $88.54
- AVG Volume (30 Days)
- BTG 32.0M
- MRUS 652.6K
- Earning Date
- BTG 08-07-2025
- MRUS 08-12-2025
- Dividend Yield
- BTG 3.61%
- MRUS N/A
- EPS Growth
- BTG N/A
- MRUS N/A
- EPS
- BTG N/A
- MRUS N/A
- Revenue
- BTG $1,972,693,000.00
- MRUS $54,732,000.00
- Revenue This Year
- BTG $55.41
- MRUS $67.27
- Revenue Next Year
- BTG N/A
- MRUS $0.49
- P/E Ratio
- BTG N/A
- MRUS N/A
- Revenue Growth
- BTG 2.63
- MRUS 42.77
- 52 Week Low
- BTG $2.20
- MRUS $33.19
- 52 Week High
- BTG $3.83
- MRUS $67.25
- Technical
- Relative Strength Index (RSI)
- BTG 38.93
- MRUS 72.89
- Support Level
- BTG $3.35
- MRUS $64.61
- Resistance Level
- BTG $3.48
- MRUS $67.25
- Average True Range (ATR)
- BTG 0.10
- MRUS 2.21
- MACD
- BTG -0.02
- MRUS 0.62
- Stochastic Oscillator
- BTG 3.70
- MRUS 91.86
About BTG B2Gold Corp Common shares (Canada)
B2Gold Corp is an international, low-cost, senior gold mining company. It has three operating open-pit gold mines in Mali, Namibia, and the Philippines and numerous exploration projects across four continents. Other assets include the Gramalote and Kiaka gold projects. The company focuses on acquiring and developing interests in mineral properties with a primary focus on gold deposits as gold production forms all its revenue. There is no dependence on a particular purchaser because the gold is sold into various markets. The company's reportable operating segments include its mining operations and development projects, namely Fekola; Masbate; Otjikoto; the Goose Project, and other mineral properties; and corporate and other.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.